Related Experiment Video
Updated: May 21, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Advances in antiretroviral therapy
Susan Olender1, Timothy J Wilkin, Barbara S Taylor
1Columbia University Medical Center, New York, NY, USA.
Topics in Antiviral Medicine
|June 20, 2012
Summary
Advances in antiretroviral therapy (ART) show promising investigational drugs and improved lifespans for HIV patients in resource-rich settings. Priorities in resource-limited settings include PMTCT and ART scale-up.
Area of Science:
- Infectious Diseases
- Virology
- Public Health
Background:
- The 19th Conference on Retroviruses and Opportunistic Infections (CROI) convened to discuss critical updates in HIV/AIDS research.
- Antiretroviral therapy (ART) has transformed HIV management, necessitating continuous evaluation of new treatments and long-term outcomes.
Purpose of the Study:
- To summarize key findings and discussions from the 19th CROI, focusing on advances in ART, novel therapeutics, and evolving challenges in HIV care.
- To highlight the shifting landscape of HIV-related mortality and the ongoing priorities in resource-limited settings.
Main Methods:
- Review of data presented at the 19th CROI, encompassing investigational drug trials, treatment outcomes in diverse patient populations, and resistance patterns.
- Analysis of findings from clinical trials and observational cohorts regarding patient survival and disease progression.
Main Results:
- Investigational drugs, including integrase strand transfer inhibitors (InSTIs) and CCR5-targeting agents, show potential for future HIV treatment.
- In resource-rich settings, non-HIV-related mortality may exceed HIV-related mortality in patients on successful ART, with lifespans approaching those of the general population.
- Prevention of mother-to-child transmission (PMTCT) and ART scale-up remain critical in resource-limited settings, alongside new data on antiretroviral resistance.
Conclusions:
- Successful ART is leading to increased longevity in HIV patients, shifting the focus towards managing non-HIV comorbidities.
- Continued efforts are needed to optimize ART delivery, address resistance, and implement PMTCT strategies, particularly in resource-limited settings.
More Related Videos
Related Concept Videos
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
02:33Retroviruses
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...